Davendra Pratap Singh Sohal MD MPH
Gastrointestinal Cancer, Hematologic Oncology
Professor of Medicine; Associate Director for Clinical Research at the University of Cincinnati Cancer Center
Join to View Full Profile
3199 Highland AveCincinnati, OH 45219
Phone+1 513-475-8500
Fax+1 513-584-4281
Dr. Sohal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Davendra Sohal is an oncologist at the University of Cincinnati. His clinical focus is gastrointestinal malignancies, and his research focus is clinical trials, including Phase I trials, precision oncology trials, and multidisciplinary studies.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2005 - 2008
University of Alabama at BirminghamMPH, Epidemiology and Biostatistics, 2003 - 2005
All India Institute of Medical SciencesClass of 2002, MD
Certifications & Licensure
OH State Medical License 2012 - 2028
PA State Medical License 2009 - 2012
NY State Medical License 2008 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
- Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Publications & Presentations
PubMed
- Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.Deborah B Doroshow, Geoffrey I Shapiro, Khanh Do, Vicki L Keedy, Haider Mahdi
Cancer. 2026-03-15 - Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.Andrew E Hendifar, Viswesh Krishna, Vrishab Krishna, Haochen Zhang, Asit Tarsode
Journal of Clinical Oncology. 2026-02-11 - Olaparib in Patients With Solid Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Daniel R Carrizosa, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Deepti Behl
JCO Precision Oncology. 2026-01-01
Lectures
- A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenoc...2019 ASCO Annual Meeting - 6/1/2019
- Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Leading-Edge Cancer Therapies Are Saving, Improving Lives in Greater CincinnatiMay 30th, 2025- 7 Big Questions About Cancer, AnsweredJanuary 29th, 2025
- University of Cincinnati Researcher Receives Catalyst Research Award to Further Cancer ResearchDecember 7th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
